Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) CEO Timothy P. Noyes sold 10,000 shares of the business's stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $24.70, for a total transaction of $247,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Timothy P. Noyes also recently made the following trade(s):
- On Monday, April 1st, Timothy P. Noyes sold 10,000 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00.
Aerovate Therapeutics Stock Down 4.0 %
NASDAQ AVTE opened at $21.60 on Friday. The company's 50 day moving average is $24.43 and its 200-day moving average is $19.08. Aerovate Therapeutics, Inc. has a 12-month low of $9.41 and a 12-month high of $32.42. The firm has a market cap of $601.78 million, a P/E ratio of -7.50 and a beta of 1.23.
Institutional Trading of Aerovate Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. UBS Group AG bought a new stake in shares of Aerovate Therapeutics in the third quarter valued at approximately $26,000. Tower Research Capital LLC TRC raised its position in shares of Aerovate Therapeutics by 136.2% in the first quarter. Tower Research Capital LLC TRC now owns 2,702 shares of the company's stock valued at $55,000 after purchasing an additional 1,558 shares during the period. Legal & General Group Plc raised its position in shares of Aerovate Therapeutics by 318.0% in the fourth quarter. Legal & General Group Plc now owns 3,235 shares of the company's stock valued at $95,000 after purchasing an additional 2,461 shares during the period. Citigroup Inc. raised its position in shares of Aerovate Therapeutics by 1,351.5% in the second quarter. Citigroup Inc. now owns 3,324 shares of the company's stock valued at $57,000 after purchasing an additional 3,095 shares during the period. Finally, Royal Bank of Canada raised its position in shares of Aerovate Therapeutics by 148.2% in the fourth quarter. Royal Bank of Canada now owns 3,475 shares of the company's stock valued at $79,000 after purchasing an additional 2,075 shares during the period.
Wall Street Analysts Forecast Growth
A.I. is a Tidal Wave - Here’s What to Buy
From Chaikin Analytics | Ad
The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone.
Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.
Get the name and ticker symbol for free - just click here.
A number of research firms have weighed in on AVTE. Wells Fargo & Company reiterated an "overweight" rating and issued a $35.00 target price on shares of Aerovate Therapeutics in a research note on Monday, April 1st. Jefferies Financial Group began coverage on shares of Aerovate Therapeutics in a research note on Monday, March 25th. They issued a "buy" rating and a $65.00 target price on the stock. Finally, Wedbush reiterated an "outperform" rating on shares of Aerovate Therapeutics in a research note on Thursday, April 4th.
Read Our Latest Research Report on AVTE
About Aerovate Therapeutics
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
